Navigation Links
ULURU Inc. Reports First Quarter 2009 Financial Results
Date:5/15/2009

0, and a net increase of approximately $458,000 in compensation costs. The net increase in compensation cost includes approximately $519,000 of share-based compensation expense after giving effect to certain vesting accelerations of stock options and restricted stock which were partially offset by certain stock option forfeitures and by savings of $77,000 relating to benefit forfeitures pursuant to the Separation Agreement with our former chief executive officer. Other factors affecting the cost increase were additional expenses of $82,000 for legal services associated with our patent filings and $70,000 for legal expense associated with SEC filings, employment matters, and trademark filings.

Interest and miscellaneous income for the first quarter of 2009 was $15,000 as compared to $125,000 for the first quarter of 2008. The decrease of approximately $110,000 is attributable to a decrease in interest income due to lower cash balances and interest yields in 2009.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex(TM) Aggregate technology and OraDisc(TM) transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com. For further information about Altrazeal(TM), please visit our website at www.altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to future financial performance of ULURU Inc. (the "Company"), development of a silver contai
'/>"/>

SOURCE ULURU Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2009 and to Provide a Business Update
2. ULURU Inc. Announces Altrazeal(TM) Clinical Experience Published in the International Wound Journal
3. ULURU Inc. Signs Offer Letter to Acquire York Pharma plc
4. ULURU Inc. (ULURU) Dealing Disclosure Requirements
5. ULURU Inc. Reports Financial Results for Fourth Quarter and Year Ended December 31, 2008
6. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2008 and to Provide a Business Update
7. ULURU Inc. Announces Appointment of Jeffrey A. Niezgoda, M.D., as Chairman of Scientific Advisory Board
8. ULURU Inc. Announces Senior Management Change
9. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2008 and to Provide a Business Update
10. ULURU Inc. Announces the Launch of the Altrazeal(TM) Website
11. ULURU Inc. Hosts Symposium on Altrazeal(TM) at the 23rd Annual Clinical Symposium on Advances in Skin & Wound Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... wealthy as the United States, it may come as a ... to adequate food due to lack of money or other ... at the University of Illinois using data from the National ... who are dealing with hunger are also facing negative health ... Americans over age 60 faced the threat of hungerthat translates ...
(Date:4/23/2014)... Oncotarget , explored tumour heterogeneity where different ... signatures within the same cancer. Such differences could ... strategies. , Firstly they confirmed the mutual exclusivity ... or BRAF mutation. Secondly, they found that lung ... that specific mutation present uniformly throughout the tumour, ...
(Date:4/22/2014)... Jersey Institute of Technology (NJIT) today to join ... of the New Jersey Innovation Institute (NJII), an ... business innovation through the leveraging of industry, government, ... Cory Booker, Panasonic Corp. of North America Chairman ... Kim Guadagno, New Jersey Secretary of Higher Education ...
(Date:4/22/2014)... 15 percent of all lung cancers are small ... often develop resistance to chemotherapy. However, researchers at ... new insights into the mechanisms leading to this ... , Chemotherapies work primarily by mediating B-cell lymphoma ... regulating cell death. Depending on their function, this ...
(Date:4/22/2014)... is the standard measurement for assessing glycemic control over ... are typically measured every few months in a laboratory, ... accurately estimates A1c using self-monitored blood glucose (SMBG) readings, ... ( DTT ), a peer-reviewed journal from Mary Ann ... the DTT website at http://www.liebertpub.com/dtt . ...
Breaking Medicine News(10 mins):Health News:More Americans in their golden years are going hungry 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2
... "Occlusions in the retinal vein could not only make you loose ... veins is so painful that the eye may have to be ... new instrument that uses a plasma to shoot tiny bullets ... vessels that supply blood to the retina drain into a single ...
... market is currently dominated by the Mumbai based ... company, is planning to enter the anti-AIDS drugs ... and west Asia, S D Kaul, the company ... Aabacavir and Indinavir products in the Indian market ...
... that can have Complication as its other name. Among the ... be the foot ulcer, as damage can be severe enough ... ulcer, a boon in disguise would be a new device ... //Such an electrical stimulation would help in the healing of ...
... procedure widely used on knees can also repair damaged ... best known for repairing knee injuries, but it is ... it is a minimally invasive surgical technique it is ... relieve different ankle problems, including ligament damage, bone chips ...
... basis. One of these latest laser techniques is helpful in ... This degenerative condition cause blood vessels to grow underneath the ... ,Eye specialists have come up with a new therapy ... of damaging the retinal tissue. ,This is a two-step ...
... active ingredient is Acetaminophen is found effective in the ... temperature in people who have had a stroke, according ... ,Rise in the body temperature during the first few ... fever, has been linked to poorer outcomes including an ...
Cached Medicine News:Health News:Blocked viens block eye sight 2Health News:Arthroscopy for Ankles 2
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
(Date:1/15/2014)... 15, 2014 The Cadence Fitness & Health Center ... the Medical Fitness Association, a non-profit organization assisting medically ... potential. The Cadence Fitness & Health Center is the ... second in the Chicagoland area. "The certification ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... April 20 Scientists from the Barbara ... presented data at the American Association for ... represents significant research advancements in the treatment ... breast cancer.(Logo: http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSLOGO )Karmanos researchers discovered ...
... Improves Survival in Animals with Clinical Symptoms of ... 20 Elusys Therapeutics, Inc. (Elusys), ... the treatment of life-threatening infectious diseases, today announced ... safety trial of Anthim(TM), a high-affinity humanized ...
Cached Medicine Technology:Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference 2Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference 3Elusys' Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study 2Elusys' Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study 3
... products for autoimmune testing feature single-well ANA ... as specific reflex tests including dsDNA, and ... (Ro), SS-B (La), Scl-70 and Jo-1. In ... full line of products for Cardiolipins (IgA, ...
... ELISA products for autoimmune testing feature single-well ... well as specific reflex tests including dsDNA, ... SS-A (Ro), SS-B (La), Scl-70 and Jo-1. ... a full line of products for Cardiolipins ...
... ELISA products for autoimmune testing feature single-well ... well as specific reflex tests including dsDNA, ... SS-A (Ro), SS-B (La), Scl-70 and Jo-1. ... a full line of products for Cardiolipins ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: